The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer

CompletedOBSERVATIONAL
Enrollment

850

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Epithelial Ovarian Cancer
Interventions
DRUG

Niraparib

Niraparib

Trial Locations (1)

138-736

Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Samsung Medical Center

OTHER

collaborator

Seoul National University Hospital

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Gangnam Severance Hospital

OTHER

collaborator

Keimyung University Dongsan Medical Center

OTHER

collaborator

Kyungpook National University Chilgok Hospital

OTHER

collaborator

Seoul St. Mary's Hospital

OTHER

collaborator

National Cancer Center, Korea

OTHER_GOV

collaborator

Pusan National University Yangsan Hospital

OTHER

collaborator

Inje University

OTHER

collaborator

Pusan National University Hospital

OTHER

lead

Asan Medical Center

OTHER

NCT06086665 - The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter